**Core Concept**
Prostate cancer is the most common primary malignancy in men that metastasizes to the bone, leading to a significant clinical burden due to bone pain, pathological fractures, and hypercalcemia. The metastasis of prostate cancer to bone is largely driven by the production of parathyroid hormone-related protein (PTHrP), which stimulates osteoclast activity and bone resorption.

**Why the Correct Answer is Right**
Prostate cancer cells can invade the bone matrix and stimulate the production of PTHrP, leading to increased osteoclast activity and bone destruction. This process is mediated by the RANK-RANKL-OPG system, where RANKL stimulates the differentiation and activation of osteoclasts, and OPG acts as a decoy receptor to inhibit this process. The metastasis of prostate cancer to bone is a major cause of morbidity and mortality in men with advanced disease.

**Why Each Wrong Option is Incorrect**
**Option A:** Breast cancer is a common primary malignancy that metastasizes to bone, but it is more common in women than men.
**Option B:** Lung cancer is a common primary malignancy that metastasizes to bone, but it is not as common as prostate cancer in men.
**Option C:** Kidney cancer can metastasize to bone, but it is a less common primary malignancy than prostate cancer.

**Clinical Pearl / High-Yield Fact**
The most common sites of bone metastasis from prostate cancer are the vertebral bodies, pelvis, and ribs, and the presence of bone metastases is a common cause of hypercalcemia in men with advanced prostate cancer.

**Correct Answer: C. Kidney cancer can metastasize to bone, but it is a less common primary malignancy than prostate cancer.**